HomeChugai Pharmaceutical Co., Ltd.

Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD

Market is not available at the momentMarket information is presented
as of 2026-11-16T06:06:04+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread15.5
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.01444 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.01444%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.00778 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.00778%
Overnight funding adjustment time22:00 (UTC)
CurrencyJPY
Min traded quantity1
Margin10.00%
Stock exchangeJapan
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close7185.3
Open7325.8
1-Year Change-9.41%
Day's Range7325.8 - 7432.6

Trade Chugai Pharmaceutical Co., Ltd. - 4519

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready